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Abstract: Bacterial toxins play a key role in the pathogenesis of lung disease. Based on their structural
and functional properties, they employ various strategies to modulate lung barrier function and to
impair host defense in order to promote infection. Although in general, these toxins target common
cellular signaling pathways and host compartments, toxin- and cell-specific effects have also been
reported. Toxins can affect resident pulmonary cells involved in alveolar fluid clearance (AFC)
and barrier function through impairing vectorial Na+ transport and through cytoskeletal collapse,
as such, destroying cell-cell adhesions. The resulting loss of alveolar-capillary barrier integrity and
fluid clearance capacity will induce capillary leak and foster edema formation, which will in turn
impair gas exchange and endanger the survival of the host. Toxins modulate or neutralize protective
host cell mechanisms of both the innate and adaptive immunity response during chronic infection.
In particular, toxins can either recruit or kill central players of the lung’s innate immune responses to
pathogenic attacks, i.e., alveolar macrophages (AMs) and neutrophils. Pulmonary disorders resulting
from these toxin actions include, e.g., acute lung injury (ALI), the acute respiratory syndrome (ARDS),
and severe pneumonia. When acute infection converts to persistence, i.e., colonization and chronic
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infection, lung diseases, such as bronchitis, chronic obstructive pulmonary disease (COPD), and cystic
fibrosis (CF) can arise. The aim of this review is to discuss the impact of bacterial toxins in the
lungs and the resulting outcomes for pathogenesis, their roles in promoting bacterial dissemination,
and bacterial survival in disease progression.
Keywords: bacterial toxins; alveolar-capillary barrier; host defense; alveolar liquid clearance;
inflammation; pulmonary edema
Key Contribution: This review summarizes actions of bacterial endo- and exotoxins in the lungs,
with a special emphasis on toxin-induced impairment of lung function, structure and host defense.
1. Introduction
Bacterial toxins are extremely powerful and sophisticated molecular weapons produced by
Gram-negative and Gram-positive pathogens [1]. Based on their structure and function, they may
exhibit diverse biological activities during infection [2]. In view of their continuous exposure to the
external environment, the lungs represent a particularly vulnerable organ for infection with bacteria
and their exo- and endotoxins. The lung is conceptually a blood-filled sponge that is interposed in
series in the bodies’ systemic circulation to take up oxygen and remove carbon dioxide; it includes a
thin epithelial alveolar layer in its alveoli that is about 100 times greater than the epithelial surface
of the skin. This thin epithelial layer needs to remain intact in order to assure efficient gas exchange
capacity [3]. The unique architecture of the airways, with 23 levels of branching, starting from the
trachea, the bronchi, and the bronchioli all the way down to the 600–700 million alveoli, provides
an impressive alveolar surface area of up to 140 m2 for gas exchange with an area of 80–90 m2 of
pulmonary capillaries. In comparison, a sphere with a similar volume as the lungs (about 4 L) would
provide a 1000-fold lower surface area. As indicated above, for the lungs to provide efficient gas
exchange, it is crucial that the alveolar-capillary barrier keeps its integrity [3–6]. Even a small alteration
in the structural or functional properties of this epithelial layer, as can be caused by bacterial toxins,
can lead to the onset or exacerbation of lung disease [4,6]. Bacterial toxins use various strategies to
alter the viability of the lung epithelial and capillary endothelial surface [4,6].
Classically, bacterial toxins are categorized into two groups, as exotoxins and endotoxins,
respectively [7,8]. Exotoxins are single polypeptides or heteromeric protein complexes, synthesized
inside either Gram-positive or Gram-negative bacteria and released by various bacterial secretion
systems from bacterial colonization sites towards target cells in the alveoli or in the systemic
circulation [7,8]. However, some exotoxins are unleashed following autolysis or upon
antibiotics-induced bacteriolysis [9]. According to their main mechanism of action, exotoxins
can be classified into three major groups, i.e., (1) membrane acting, (2) membrane damaging,
and (3) intracellular effectors [10]. Membrane acting toxins bind to specific receptors on the surface of
host cells and subsequently transduce transmembrane signals [10]. Membrane damaging toxins form
pores or disrupt lipid bilayers to manipulate ion homeostasis, as such launching pathways involved in
cell death and barrier dysfunction, like Ca2+ [10,11]. Intracellular effector toxins manipulate target
molecule(s) by translocating an active enzymatic component into the cell [10]. All of these mechanisms
may be involved in bacterial toxin-induced lung injury.
Exposure to bacterial toxins may cause direct alveolar epithelial and capillary endothelial cell death.
Epithelial cells death as well as decreased barrier function increases permeability of the alveolar-capillary
barriers and thus fosters the generation of pulmonary permeability edema. Moreover, increased cell
death in the alveolar compartment perturbs type I and II alveolar epithelial (AT1, AT2)-mediated
alveolar fluid clearance and increases the risk of disordered repair, which can lead to a fibroproliferative
response as seen in the acute respiratory syndrome (ARDS) [6]. Injury to the alveolar type I cells,
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the major component of the alveolar barrier, is a key determinant of disease evolution of acute lung
injury (ALI) and ARDS. As such, the impact of toxins on AT1 should be carefully investigated [6].
Moreover, some toxins can impair the function of ion channels on the alveolar cell surface, or can
form membrane pores, both of which can contribute to ion dysregulation and the launch of molecular
pathways leading to epithelial barrier dysfunction and cell death [9,12–22]. Bacterial toxins can also
target epithelial cell cilia, respiratory mucosa, and tight junction (TJ) proteins, which are important
components of the lung epithelial barrier [23–29]. As the degree of AT1/2 and capillary endothelial cell
injury are key determinants of ALI- and ARDS, the destructive impact of toxins should be carefully
considered [6]. Moreover, pore-forming toxins, such as the G-positive cytolysins pneumolysin (PLY)
and listeriolysin-O (LLO), can cause ion flux dysregulation (especially Ca2+) and launch molecular
pathways fostering epithelial and endothelial barrier dysfunction and cell death [9,11–22]. In addition,
epithelial cell cilia, respiratory mucosa, and TJ proteins are other targets of bacterial toxins at the
pulmonary barrier [23–29].
Endotoxins, such as lipopolysaccharides (LPS) are the major constituents and protective elements
of the outer membrane of Gram-negative bacteria [30]. LPS is comprised of three domains, which are
genetically, chemically, and functionally distinctive [31]. These domains include the lipid A, the core,
and the O-antigen [32,33]. LPS has a broad range of biological activities, which can disrupt lung
function and is considered a causative factor in chronic lung diseases, including chronic obstructive
pulmonary disease (COPD) and cystic fibrosis (CF) [34,35]. LPS administration was also shown to
induce bronchopulmonary hyperresponsiveness leading to asthma. However, in this case eosinophils
are not involved, but rather neutrophils and the cytokine Tumor Necrosis Factor [36,37]. LPS moreover
exerts important pathogenic roles in ALI/ARDS and pneumonia. Endotoxin can foster bacterial
persistence by facilitating biofilm formation, which is especially important in genetic diseases, such as
CF [38–40].
During infection, cells of both the innate and adaptive immune response are engaged. Alveolar
macrophages (AMs) are the guards of innate immunity in the alveolar space and can be resident or
recruited from the systemic circulation. AMs have developed different inflammatory strategies to attack
the pathogen as well as anti-inflammatory strategies for resolution of inflammation [41]. As part of their
anti-inflammatory mechanisms, AMs phagocytose apoptotic cells (efferocytosis) and thereby prevent
them to release toxic components, such as pro-inflammatory cytokines, chemokines, and leukotriene
C4. They moreover induce the release of anti-inflammatory and repair factors, including transforming
growth factor β1 (TGF-β1), prostaglandin E2 (PGE2), and platelet-activating factor (PAF) [42–45].
Although PGE2 was shown to be involved in both pro- and anti-inflammatory activities, its capacity
to activate endothelial nitric oxide synthase (eNOS)-mediated nitric oxide generation was shown to
significantly blunt endothelial leukocyte interactions [46,47]. Moreover, mice defective in microsomal
prostaglandin E synthase-1, a key enzyme in PGE2 synthesis, were shown to have significantly increased
lethality and a defective pulmonary clearance of Streptococcus pneumoniae [48].
Bacterial toxins can hinder the function of AMs and neutrophils and, thereby, disturb the early
innate antibacterial host immune reaction, as such facilitating a microenvironment conducive for
bacterial colonization and proliferation [49,50].
Various respiratory tract disorders are associated with bacterial toxins. During the infection,
diverse drivers, mediators, triggers, and catalysts contribute to infection that are coupled to feedback
loops systems. Obviously, simple cause and effect paradigms are incapable of capturing these complex
circumstances. Therefore, to understand such complex relationships, and in order to develop efficient
antimicrobial therapies, it is essential to identify the molecular pathways that have to be targeted
as well as the mechanisms mediating their dysregulation. Accordingly, without trying to cover all
pathways, this review aims to summarize some current knowledge gained from published data and
from our own studies on the role of bacterial toxins in the pathogenesis of acute and chronic lung
diseases, both of which can have a profound impact on the life quality of individual patients and their
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relatives. We will moreover briefly discuss the impact of pathogenic bacteria and their toxins in lung
disease pathogenesis.
2. Staphylococcus aureus (S. aureus)
S. aureus is a spherical Gram-positive aerobic opportunistic pathogen [51] with a diameter of
about 0.5 to 1.0 µm [52], which often forms clusters [53]. It is a ubiquitous microorganism commonly
found in normal human flora, such as skin, nasal passage, axillae, and repository tracts, but it is also
the causative agent of blisters, food poisoning, and pulmonary infection [54–61]. The commonly
observed S. aureus infection in CF patients is of high clinical importance and usually occurs before
Pseudomonas aeruginosa infection. This represents one of the main causes of the recurrent acute or
persistent pulmonary infections and progressive decline in lung function characteristic for the genetic
life-threatening CF multisystem disorder. Pulmonary infections due to S. aureus can also occur in the
community or hospital setting among individuals with S. aureus colonization of the skin or of the nares,
particularly in the context of intubation. S. aureus pneumonia may occur after viral pneumonia, or
typically during right-sided S. aureus endocarditis with septic pulmonary emboli.
Due to its colonization and virulence properties, S. aureus is able to cause community- and
hospital-acquired infectious diseases [61]. The pathogen induces host-damaging responses by means
of surface-located protein factors, polysaccharides and secreted virulence factors [62,63]. The highly
regulated toxin production system of S. aureus is relevant to human disease [64]. In the following
paragraphs, we will discuss the contribution of the S. aureus-derived toxins alpha-hemolysin/alpha-toxin,
beta-toxin, and Panton–Valentine leukocidin to lung injury.
2.1. Alpha-Hemolysin (Hla)
Hla is a small β-barrel archetypal pore-forming toxin with a molecular mass of 34 kDa
expressed by most strains of S. aureus as a water-soluble monomer [12,65]. Hla contributes to
the pathogenesis of ventilator-associated pneumonia [64,66,67] through forming pores, manipulating
structural and functional properties of alveolar epithelium, capillary endothelium, and AMs,
and provoking inflammatory mediator release [67–70]. Pore formation occurs upon binding of
Hla to its receptor A Disintegrin and Metalloprotease 10 (ADAM-10) in the target cell membrane,
which induces oligomerization, self-assembly, and the generation of a lipid-bilayer mushroom-shaped
hexameric/heptameric channel [67]. In comparison to other pore-forming toxins, such as pneumolysin
(PLY) and listeriolysin-O (LLO), Hla makes smaller pores with a diameter of only about 1–2 nm that
are permeable for Ca2+, Na+, K+, Cl−, ATP, and molecules with low molecular weight (between 1
and 4 kDa) [12,71]. Like LLO and PLY, Hla fosters transmembrane influx of Ca2+, which ultimately
leads to the development of pulmonary edema [12,20]. Binding of Hla to ADAM10 causes activation
and upregulation of its metalloprotease activity leading to the pathologic cleavage of its substrates,
including epithelial E-cadherin and vascular endothelial (VE)-cadherin, with concomitant loss of
barrier function [70–76]. Moreover, Hla has the ability to disrupt endothelial-cell TJs through activating
acid sphingomyelinase and release of ceramide [69]. Ceramide produced by acid sphingomyelinase is
associated with PAF-induced pulmonary edema [72].
Alveolar epithelial cells represent sensitive targets to an Hla assault [73], since the pore-forming
toxin impairs the alveolar-capillary barrier of the lung in a rat model of S. aureus-induced
pneumonia [74,75], upon inducing alterations in cell shape and by promoting formation of paracellular
gaps in human airway epithelial cells [75,76]. Hla pore formation in bronchial epithelium causes
the release of cytosolic ATP to the extracellular space [76,77], which increases ciliary beat frequency
in tracheal cells via both P2X and P2Y receptors [78]. Hla, moreover, induces mucus secretion in
goblet cells [79,80] and fosters Interleukin 6 (IL-6) secretion by small human airway epithelial cells [81].
In addition, Hla damages the function of rabbit AMs in vitro by reducing their phagocytic activity [82].
Hla, also, contributes to lung and liver injury by preventing adequate platelet repair and exacerbating
the host inflammatory response, leading to the release of proinflammatory cytokines such as IL-1β, IL-6,
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tumor necrosis factor (TNF), Interleukin 18 (IL-18), and chemokines such as Interleukin 8 (IL-8/CXCL8)
and macrophage inflammatory protein 2 (MIP-2) [82–87]. Furthermore, it has been shown in a murine
model of severe pneumonia that the pore-forming activity of Hla potentiates bacterial virulence via
activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome in AMs,
which stimulates the production of IL-1β and IL-18 and induces necroptosis [86,87].
2.2. Beta-Hemolysin (Hlb)
Hlb/beta-toxin (β-toxin) is a Mg2+ -dependent neutral sphingomyelinase and cytolysin, with a
molecular weight of 35 kDa, secreted by certain strains of S. aureus [88,89]. Hlb can cause lung injury
by means of enhancing neutrophil infiltration in a syndecan-1 dependent manner, accompanied by
leakage of serum proteins into the lung tissue and exudation of proteins into the airways [89]. In vitro
Hlb can decrease or halt ciliary beat frequency in rabbit respiratory epithelium dependent on its
concentration and exposure period [27].
2.3. Panton-Valentine Leukocidin (PVL)
PVL is a non-hemolytic leukocytolytic exotoxin expressed by many methicillin-resistant S. aureus
strains [90,91]. It is a two-component (32 and 34 kDa) pore-forming toxin with membrane-disturbing and
cytolytic capabilities [92]. PVL-producing strains can cause severe lung necrosis, alveolar hemorrhage,
pulmonary edema formation, lung hemoptysis, and sometimes death, which are all characteristics
of human necrotizing pneumonia [93]. PVL is cytotoxic towards the lung epithelium, as it induces
necrosis and/or apoptosis of AT1 cells [28]. PVL induces lung inflammation leading to acute lung injury
in a rabbit model of necrotizing pneumonia, fostering infiltration of AMs and polymorphonuclear
neutrophils (PMNs) through the release of chemokines such as monocyte chemotactic protein 1 (MCP-1)
and IL-8/CXCL8 (a potent neutrophil attractant) [93–96]. Following PMN migration into the alveolar
space, PVL induces PMN lysis, which leads to release of granule contents, such as proteases and
reactive oxygen metabolites. Proteases together with oxidants can cause cell death of alveolar type 1
cells and perforation of the alveolar epithelial-interstitial and interstitial-endothelial barrier, providing
a path for the influx of fluid and proteins from the vascular space into the alveolus; thus, ending up
with pulmonary edema formation and ALI [97–100]. PVL-mediated pore formation induces influx of
Ca2+, in PMNs, which in turn increases intracellular Ca2+ levels [93]. Depending on the concentration
of PVL, increased intracellular Ca2+ can either induce PMN degranulation, apoptosis, or -at the highest
doses- octameric pore-mediated necrosis [93,95]. The size of the pore formed by PVL in PMNs is
dependent upon ionic environmental conditions [93].
3. Pseudomonas aeruginosa
The Gram-negative bacterium P. aeruginosa is an opportunistic pathogenic bacterium [101] that
normally inhabits soil and surfaces in aqueous environments [101]. P. aeruginosa is highly adapted
to human hosts, has a moderate predilection to immunocompromised hosts, and can cause acute
infections of different tissues and organs, including lungs, as is the case with ventilator-associated
pneumonia, where it is the most common multi-drug resistant bacterium and probably the most serious
etiologic agent [2]. Individual strains often produce a considerable number of toxins and surface
components that associate with virulence properties.
P. aeruginosa causes persistent colonization and infection in CF patients and it is the most frequent
infective agent leading to death in CF [102]. The large genome of P. aeruginosa encodes a wide range
of different metabolic enzymes, which confers the bacterium with high nutritional versatility [102].
Counter-intuitive to the concept that bacteria cause disease by expressing their virulence factors,
CF colonization is promoted by downregulation of virulence factors. The immunologic response
to such virulence factors within colonizing strains promotes the emergence of mutated variants
that are better at evading pulmonary host immune mechanisms. Thus, the P. aeruginosa flagellin
synthesis is frequently downregulated in the CF lung, most probably to avoid detection by host
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defense mechanisms. Flagellin is highly immunogenic and may be detected by pattern recognition
receptors [103]. Furthermore, virulence factors that are no longer needed for chronic colonization
accumulate random mutations in the genes responsible for their expression in strains that subsequently
colonize the airways.
The persistence in the face of intact host defense mechanisms early in the life of many patients
with CF is a characteristic of colonizing bacteria. Thus, defects in mucociliary clearance and in host
killing of bacteria in CF promote their persistence [104]. In CF, the lack of the expression of the cystic
fibrosis transmembrane conductance regulator (CFTR) gene causes depletion of the periciliary liquid
layer at the surface of the tracheal epithelium, which and inhibits clearance of the mucus coat from the
lung, bronchial tree, and trachea [105]. With the lack of clearance of the mucus coat, bacteria that live
in the mucus may colonize the tracheobronchial tree and lung and the patient ultimately suffers from
lung infection.
Isolates from CF Patients with newly identified P. aeruginosa infection frequently have mucoid-and
biofilm-forming phenotypes, which are generally associated with adaptation towards chronic
persistence in the CF lung [104]. Important steps include the downregulation of the production
of toxins, flagellum and pili, the loss of lipopolysaccharide “O” side chains, and the expression of the
polysaccharide alginate giving the bacterium a “mucoid phenotype” promoting biofilm formation,
thereby protecting the bacterium against phagocytosis and promotes tissue damage [104].
CF patients lack effective mechanisms for killing P. aeruginosa and are therefore more susceptible
to this pathogen than others [106]. The high chloride concentrations in pulmonary secretion due to the
defective CFTR is critical because this high chloride environment inactivates the secreted antimicrobial
respiratory epithelial peptides beta-defensin-1 and -2 [107–110], increases inflammatory mediators by
polymorphonuclear neutrophils and diminishes the ability of neutrophils to kill P. aeruginosa [110].
Ivacaftor, which restores CFTR function, was shown to reduce P. aeruginosa culture positivity in CF
patients [111]. The following paragraphs will discuss the major virulence factors of P. aeruginosa.
3.1. Exotoxin A (P-ExA)
P-ExA is a 66 kDa exotoxin [112] secreted by the type II secretion system (T2SS) of the P.
aeruginosa strain PA 103 [112]. P-ExA is a membrane-damaging toxin that can form both pH-
and temperature-dependent α-helixes pores, leading to the generation of pores of about 2.8 nm in
diameter [113–115]. It has been reported that during respiratory tract infections with P. aeruginosa,
P-ExA can facilitate both the growth of P. aeruginosa [116] and promote cell infiltration in the lungs [117].
It is a weak inducer of IL-1- β, IL-6, MIP-1α and MIP-2, but does not induce TNF [118] and is an
inhibitor of lung IL-18 secretion [119]. To disrupt pulmonary barrier function, P-ExA was shown to
increase paracellular permeability in AT2 cells (by preventing the repair of damaged tight junctions [26])
and in the bovine pulmonary artery endothelial cells [120].
3.2. Exoenzyme S (Exo S) and Exoenzyme T (Exo T)
Exo S and Exo T are bi-functional type-III cytotoxins of Pseudomonas aeruginosa that share 76%
primary amino acid homology and contain N-terminal Rho GTPase-activating proteins (GAP) domains
and C-terminal adenosine diphosphate (ADP)-ribosylation domains [121,122]. The Rho GAP activities
of Exo S and Exo T appear to be biochemically and biologically identical, targeting Rho, Rac, and
Cdc42. Expression of the Rho GAP domain in mammalian cells results in the disruption of the actin
cytoskeleton and interference of phagocytosis. Expression of the ADP-ribosyltransferase domain of
Exo S elicits a cytotoxic phenotype in cultured cells, while the expression of Exo T appears to interfere
with host cell phagocytic activity.
Exo S is a 49 kDa-secreted cytotoxin [121,122] with an enzymatic activity that is translocated by
its type III secretion system (T3SS) into the cytosol of eukaryotic cells [29,123]. Whereas P. aeruginosa
type III secretion performs a dominant role in acute infections, emerging evidence suggests that it
may actually be selected against in chronic infections, such as those afflicting individuals with CF.
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Many CF patients have antibodies against type III effector proteins [124], suggesting that these factors
are expressed at some point during infection. However, P. aeruginosa strains gradually lose the ability
to secrete type III proteins over time in the CF airways [125].
It has been reported that Exo S can cause severe pulmonary-vascular breakdown [29], bacterial
persistence, and progression of pneumonia [29,126]. Exo S causes disruption of bronchial epithelium
cells and AT1 [29]. It damages the membrane of AT1, disrupts TJs, and causes cell death [29,127].
By annihilating focal adhesions, retraction of endothelial cells, and a rupture of the endothelial
monolayer, Exo S modulates lung endothelial permeability [128,129]. During initial phases of
pneumonia, P. aeruginosa injects Exo S into leukocytes such as neutrophils and at later time points
disrupts AT1 thereby facilitating dissemination of P. aeruginosa from the lung to the bloodstream [29].
In addition, Exo S targets substrates of host cells, which are essential for preservation and viability of
AT1 tight junctions [29]. Exo S can also cause alteration of pulmonary structure [129]. Intratracheal
instillation of purified Exo S into rat lungs causes membrane damage of AT1 cells by dislodging
membranes, accumulation of inflammatory cells, fibrinous exudation, and destruction of the bronchial
epithelial layer [129].
In a mouse model of pneumonia, Exo S can cause the progression of inflammation leading
to neutrophil infiltration into the lung [130]. Moreover, during early pneumonia, Exo S is injected
into recruited neutrophils and into type I pneumocytes at later time points [29]. Exo S inhibits the
phagocytic capacity of macrophages and neutrophils [130]. Interestingly, the injection of Exo S in type
I pneumocytes causes an increase in their size during pneumonia [29]. In addition, by activating TLR2
and TLR4, Exo S induces a range of inflammatory responses [131].
Exo T is also secreted through the T3SS of P. aeruginosa [132]. Exo T inhibits lung epithelial
wound repair by targeting cells at the edge of the wound in vitro and provoking a collapse of the actin
cytoskeleton, which ends up to cell rounding and cell detachment [133]. To evade phagocytosis of
immune effector cells, Exo T inhibits the internalization of P. aeruginosa by phagocytes and epithelial
cells [133,134]. It also causes apoptosis of epithelial cells [134]. Similar to Exo S, Exo T ruptures
the endothelial monolayer. By disrupting the pulmonary barrier function [129], Exo T causes the
dissemination of bacterial and inflammatory mediators from the airspace into the systemic circulation
that leads to bacteremia and sepsis. In vitro and in vivo data show that during P. aeruginosa induced
pneumonia, Exo T increases interferon gamma (IFN-γ) production by natural killer (NK) cells in
lungs [135–137].
3.3. Exotoxin U (Exo U)
Exo U is a 74 kDa phospholipase secreted by T3SS of P. aeruginosa directly into cytosol of targeted
cells [138,139]. In contrast to, e.g., Exo S, Exo U has phospholipase A2 activity with broad substrate
specificity [140]. Exo S and Exo U are rarely found together in one bacterial strain [141]. Despite their
different enzymatic activities, Exo S also Exo U can both provoke cell death and epithelial damage,
vascular hyperpermeability, platelet activation, and thrombus formation. Exo U can moreover impair
phagocytosis ability of AMs and cause macrophage necrosis [142–144]. Exo U activates nuclear
factor kappa light chain enhancer of activated B cells (NF-κB) and stimulates IL-8/CXCL8 secretion in
P. aeruginosa-infected epithelial and endothelial cell lines [145], which can in turn augment neutrophil
infiltration, but it blunts the production of IL-18 [141]. As such, both Exo U and Exo S, contribute to
lung injury through the course of pneumonia, ALI, bacteremia and sepsis [142–145].
3.4. Exotoxin Y (Exo Y)
Exo Y is a 42 kDa adenylate cyclase secreted and translocated by the T3SS of P. aeruginosa to
the host cell cytosol [146,147]. As a soluble cyclase, Exo Y is a soluble cyclase functionally similar
to Bacillus anthracis edema factor and Bordetella pertussis adenylate cyclase toxin (cyaA) [148]. Exo
Y contributes to the acute pathogenicity of P. aeruginosa by destruction of lung barrier integrity,
decreasing secretion of different mediators, enhancing apoptotic activity, hemorrhage, formation
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of interstitial edema in alveolar septa and infiltration of the perivascular space with erythrocytes
and neutrophilic granulocytes [149]. Exo Y disrupts the integrity of the pulmonary barrier by
inducing epithelial and endothelial cell rounding upon modulating the actin cytoskeleton in the
cell margins [149–151]. It inhibits endothelial cell proliferation and vascular repair following lung
injury by targeting microtubules [151]. Following introduction of Exo Y into the host cell cytoplasm,
it generates cyclic nucleotides [147] to activate protein kinases [152]. Such activation causes tau
phosphorylation and microtubule breakdown [153], which leads to inter- endothelial cell gap formation,
pulmonary vascular dysfunction and thereafter establishment of pulmonary edema, which occurs
as a consequence of impaired alveolar-capillary barrier disruption, combined or not with reduced
alveolar fluid clearance capacity [4,5,152,153]. In addition, Exo Y impairs recovery of the endothelial
cell barrier, decreasing migration, proliferation, and lung repair [151]. Exo Y, somewhat paradoxically,
inhibits rather than induces pro-inflammatory cytokine and chemokine production in macrophages,
as such decreasing secretion of IL-1β, IL-6, TNF, and of the chemokine IL-8/CXCL8 [154,155].
3.5. Exolysin A (Exl A)
Exl A is a 172 kDa two-partner pore-forming toxin, secreted by an outlier family of P. aeruginosa
strains that are devoid of T3SS and all TSS3-toxins [2,114,151,156–158]. It can cause devastating injuries
in infected lungs by altering plasma membrane permeability, disrupting the alveolar-capillary barrier
leading to pulmonary hemorrhages and promoting bacterial growth in the lungs and dissemination into
the body [2,159,160]. Exl A can cause permeability in the plasma membrane of host cells by induction
of plasma membrane rupture in epithelial, endothelial, and immune cells [161]. It creates pores with a
diameter of about 1.6 nm by employing the type four (IV) pili for adhesion of bacteria to the target cell
and facilitating direct contact between bacteria and host cell walls [114]. Release of Exl A in the local
medium close to the host cell membrane leads to insertion into the host cell membrane, oligomerization,
and pore formation. Like other pore-forming toxins, Exl A promotes junction disruption to facilitate
the trafficking of small molecules such as Ca2+ and K+ [2,114]. Influx of Ca2+ into the cytosol,
dissociates calmodulin from pro-ADAM10 [160], as such, allowing mature ADAM10 (m-ADAM10) to
cleave the adherens junction proteins E- and VE-cadherin, leading to cell-cell junctions rupture [160].
The observed leakage of lactate dehydrogenase (LDH) indicates moreover the impending death of the
infected host cells [2,114,160,162].
Exl A enables bacteria to proliferate in the lungs and to spread to other organs [159], such as the
spleen of mice infected through a pulmonary pathway [157]. Thus, Exl A causes both the disruption
of the alveolar-capillary barrier and necrosis of the epithelial and endothelial cells, culminating in
hemorrhagic pneumonia, which in turn promotes bacterial dissemination [159]. In addition, Exl
A induces the efflux of K+ through thereby altering the concentration of cytosolic K+ and eliciting
activation of the NLRP3/Apoptosis-associated speck like protein containing a caspase recruitment
domain (ASC) inflammasome. The resulting caspase-1 activation will cause the release of IL-1β [2].
Exl A can also induce inflammatory pyroptotic death of macrophages through the activation of the
NLRP3 inflammasome [114].
3.6. Alkaline Protease (AP)
AP is a 50 kDa Zn2+-metalloprotease exotoxin expressed by the type I secretion system (T1SS)
of P. aeruginosa [163–165] associated with keratitis, otitis media, CF, and bacteremia [166–169] that
can lead to potentially fatal outcomes in patients with CF, as well as in immunocompromised
individuals [165,170]. AP activates the epithelial sodium channel (ENaC) in CF patients, largely due to
cleavage and maturation of the γ subunit [169]. Activation of ENaC decreases airway surface liquid
volume and as such decreases mucociliary clearance in the lungs of CF patients, which facilitates
Pseudomonas colonization [169].
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3.7. Lipopolysaccharide (LPS) from P. aeruginosa
In general, G− bacterial endotoxin or LPS can exert its functions either extra- or intracellularly.
In response to extracellular LPS, toll-like receptor 4 (TRL4) induces both a transcriptional innate and
adaptive immune response, characterized by increased cytokine expression and Nod-like Receptor
(NLR)-mediated canonical inflammasome activation [171–173]. In the alveolar space, LPS may
provoke the release of inflammatory mediators in resident cells, including TNF, IL-1β, and IL-6 [174].
The TLR4-MD-2 signaling complex can distinguish LPS chemotypes (smooth versus rough) and
functions in a MyD88-dependent or a CD14, MyD88-independent manner [175]. The MyD88-dependent,
but not the MyD88-independent pathway of TLR4 signaling was shown to be crucial in clearing
non-typeable Haemophilus influenzae from the mouse lung [176]. LPS can moreover stimulate
granulocytes to release neutrophil extracellular traps (NETs) in a process termed NETosis, albeit not
very potently.
LPS provokes alveolar-interstitial and interstitial-endothelial barrier breakdown, leading to
respiratory failure [38,177]. Intracellular LPS from, e.g., Escherichia coli, Salmonella typhimurium, Shigella
flexneri, and Burkholderia thailandensis can activate mouse caspase 11 to cause pyroptotic cell death
and IL-1β processing in a gasdermin D-dependent manner [178–180]. In human cells, the orthologs
of mouse caspase-11, i.e., caspases 4 and 5, can potentially cause similar responses [172]. As such,
LPS can affect both the innate (TLR4) and the adaptive immune system, the latter upon intracellular
LPS-mediated IL-1β and IL-18 release, since these IL-1 family members are involved in both innate
and adaptive immunity [173].
LPS from P. aeruginosa (LPSPA) is produced in both smooth and rough forms to protect the
bacterium against host defense mechanisms. It enables P. aeruginosa to live in different ecological niches
and to establish an infection there [181]. More importantly, it is associated with the pathogenesis of
P. aeruginosa during COPD, CF, and pneumonia [34,35,38]. In alveolar epithelial cells, LPSPA regulates
airway epithelial ion transport at least by three ways [182–184]. Firstly, it can induce the release of
ATP from alveolar type 2 (AT2) cells leading to activation of the phospholipase C-Protein kinase C
(PLC-PKC) pathway through stimulation of the P2Y2 purinergic receptors. Ultimately, this activation
cascade decreases the surface expression and activity of ENaC [182]. Secondly, LPSPA activates ERK1/2
and p38 MAPK pathways, which attenuate ENaC-α mRNA expression by reducing ENaC-α promoter
activity [183]. Thirdly, LPSPA provokes Ca
2+ release from thapsigargin-sensitive stores and Ca2+ entry
by both transient receptor potential (TRP) and L-type calcium channels with subsequent stimulation
of Cl− secretion by the CFTR channel in human bronchial epithelium cells [184]. These actions
arise within a few minutes and could be considered the first perceived signals by the epithelial cells
during P. aeruginosa infection [184]. Accordingly, in CF patients, due to the lack of functional CFTR,
the pro-secretory effect of LPS on Cl- transport would be expected to be muted and might assist the
persistence of infection by reduced mucociliary clearance [184]. Indeed, in the normal lung, mucociliary
clearance is increased by P. aeruginosa as a defense strategy [184].
In addition, LPSPA can modulate mucin overproduction in chronic inflammatory airway
diseases [34]. LPSPA induces the production of reactive oxygen species (ROS) in human airway
epithelial cells [34] through protein kinase C (PKC)-NADPH oxidase signaling pathways. These events
in turn foster the release of transforming growth factor-α (TGF-α), which upregulates expression
of the gel-forming mucin MUC5AC [34]. MUC5AC is generally considered a major airway mucin,
produced by goblet cells in the tracheobronchial surface epithelium, and is highly expressed, not only
in human bronchial epithelium, but also in bronchial submucosal glands. It has the typical viscoelastic
property of mucin that is needed for clearance and maintenance of integrity of the epithelium in
order to protect from dehydration and from potential pathogens [185]. As such, upregulation of
MUC5AC is an important factor associated with morbidity and mortality of patients with asthma,
COPD and CF [34,186,187]. In vitro and in vivo data further show that LPSPA induces the production
of ROS in human airway epithelial cells [34], enhances paracellular permeability of airway epithelium,
and significantly increases lung inflammation [188]. During infection by P. aeruginosa, LPSPA activates
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mast cells, which decrease the levels of claudin-1 and occludin gene expression that results in pulmonary
permeability [189,190].
4. Salmonella enterica
S. enterica is a Gram-negative, motile rod-shaped facultative intracellular
pathogenic bacterium [191,192]. Although Salmonella species are mainly recognized to cause
foodborne disease [193] and are not considered as typical respiratory pathogens, their LPS may
nevertheless cause significant perturbations in lung function [194,195].
LPS of S. enterica (LPSSE)
Intratracheal aerosolization of LPSSE in rats resulted in ARDS, characterized by neutrophilic
alveolitis, capillary endothelial damage, platelet sequestration, and pulmonary edema [196].
5. Escherichia coli
E. coli is a Gram-negative, rod-shaped, facultative anaerobic bacterium [197]. It is ubiquitous in
the human gastrointestinal tract [198]. Pulmonary infections by E. coli are relatively rare [199], but can
lead to E. coli pneumonia both in the community and in the hospital [200]. LPSSE is, however, the main
inducer of sepsis-related ARDS. As such, many studies have used LPS from E. coli to elucidate the
details of endotoxin-induced lung injury [201–218].
5.1. LPS of E. coli (LPSEC)
LPSEC can contribute to the pathogenesis of ALI and ARDS [37,188–190], characterized by
infiltration of neutrophils and macrophages, the release of pro-inflammatory mediators such as
IL-1β, IL-6, IL-8/CXCL8, IL-18, IL-23, TNF, and MIP-2, the decreased release of anti-inflammatory
cytokines such as IL-4 and IL-10, and the disruption of pulmonary alveolar epithelial-capillary barrier
integrity [204,206–211]. In the respiratory epithelium, LPSEC can modulate α-ENaC expression [212],
damage bronchiolar and alveolar epithelial cells [201], stimulate AT1 cells to produce a number of
pro-inflammatory mediators [213], and increase expression of a calcium-activated chloride channel
(CLCA1) [214].
LPSEC causes a pulmonary vascular leakage, and endothelial cell apoptosis, as well as cell
contraction, actin reorganization and, thus, loss of the endothelial barrier integrity [201–203,215–217].
However, in PMNs, LPS was shown to rather blunt apoptosis [218]. LPS downregulates SOX18,
which is a barrier-protective protein, which further increases the vascular leak [219]. Moreover,
LPSEC can cause PMN-dependent lung injury in rabbits through the recruitment and activation of
PMNs, with the chemokine IL-8/CXCL8 playing an important role in this biological action [207].
5.2. Exotoxins of E. coli
Apart from its endotoxin (LPSEC), E. coli also expresses several exotoxins. These include, among
others, Hemolysin (HlyA), cytotoxic necrotizing factor-1 (CNF-1), and vacuolating autotransporter toxin
(Vat) (reviewed in [220]). With the exception of HlyA, the relevance of these exotoxins for lung injury
associated with E. coli infections in man remains rather understudied. HlyA is a 110-kD pore-forming
exotoxin that has been implicated in the development of acute lung injury [221]. In particular, AMs are
sensitive targets for HlyA attack, and respond with a marked pro-inflammatory lipid mediator synthesis.
HlyA is considered the prototypical type I secretion protein in G− bacteria. All repeats-in-toxin (RTX)
family members share a motif of nine amino acid repeats near the C-terminus involved in Ca2+-binding.
Unlike the homologous RTX leukotoxins, E. coli HlyA is cytotoxic to many different host cell types
and towards many species of hosts [222]. CNF1 is a 115-kD protein catalyzing the deamidation of a
conserved glutamine residue causing the activation of three members of the Rho family of GTP-binding
proteins, i.e., RhoA, Cdc42, and Rac. This causes cytoskeletal rearrangements, cell cycle disruption,
Toxins 2020, 12, 223 11 of 34
and interruption of signaling pathways [223]. CNF1 treatment of PMNs increased their production
of ROS but blunted their ability to phagocytize bacteria [224]. Vacuolating AT toxin (Vat) has been
demonstrated to be a significant virulence factor in avian pathogenic E. coli using respiratory and
cellulitis infection models of disease in broiler chickens [225].
6. Bordetella pertussis
B. pertussis is a Gram-negative, strictly aerobic, encapsulated, non-spore forming coccobacillus [226].
This microorganism is highly contagious and causes acute respiratory illness through person- to-person
transmission by aerosolized respiratory droplets. It adheres to ciliated cells of the upper and
lower respiratory tract to establish colonization using its numerous virulence factors including its
exotoxins [227]. B. pertussis causes severe paroxysmal coughing, known as whooping cough, in adults
and infants [227–229], sometimes also accompanied by pneumonia or otitis media.
6.1. Pertussis Toxin (PTX)
Pertussis toxin (PTX) is a 105 kDa [230] multi-subunit exotoxin secreted across the bacterial outer
membrane by a type IV secretion system, i.e., a transport platform used by B. pertussis to secrete
its virulence factors in order to invade the host cells as the first-line adhesion factor [227,231–233].
The PTS1 subunit of PTX is an adenosine diphosphate (ADP)-ribosyltransferase that inactivates
the alpha subunit of heterotrimeric Gi/o proteins [234]. PTX plays a major role in the pathogenesis
of infants’ pertussis, modulation of immune and inflammatory response of the infected host and
paroxysmal cough of pertussis [234]. PTX promotes bacterial dissemination beyond the initial site of
infection and in severe infant pertussis; PTX mediates leukocytosis as well as pulmonary hypertension
through impacting other organs outside the respiratory system [230,234]. PTX facilitates colonization
of the respiratory tract by B. pertussis, exacerbates and prolongs airway inflammatory responses
and inhibits the resolution of inflammation [230,235,236]. In vitro and in vivo studies have further
demonstrated that PTX reduces pulmonary barrier function [237,238]. It increases PKC-mediated
endothelial permeability in pulmonary artery endothelial cells in vitro [239–241]. PTX signals through
G protein-coupled receptors (GPCRs), which are involved in the biogenesis and maintenance of
epithelial tight junctions. As such, pulmonary PTX instillation leads to the formation of pulmonary
edema in mice [230,240,242].
In the early phase of infection, PTX inhibits neutrophil recruitment to the respiratory tracts [243,244],
whereas in later phases, PTX aggravates neutrophil recruitment into the alveolar space through
the increased production of neutrophil-attracting chemokines including CXCL1, CXCL2, CXCL5,
and IL-17A by AMs [245]. By targeting resident airway macrophages, PTX inhibits their anti-bacterial
activity [246], but the exact mechanisms for suppression of AM activity remains to be further
investigated [247]. PTX can cause -or at least represents a co-factor of- pulmonary hypertension
through inhibition of GPCRs in the heart and in the lungs during severe pertussis infection [247].
PTX acts on inflammation together with its other physiological actions that are involved in the pathology
of coughing [230]. Accordingly, therapeutic targets of PTX activity can be considered beneficial in
order to decrease the severity of the patient’s’ cough during infection [230].
6.2. Adenylate Cyclase Toxin (ACT)
Adenylate Cyclase Toxin (ACT) is a pore-forming exotoxin of 200 kDa [248] that is a member of the
repeats-in-toxin (RTX) family of proteins, secreted by the type I secretion system by all virulent strains
of B. pertussis [249,250]. It is also a calmodulin-activated adenylate cyclase enzyme, a multifunctional
molecule bearing both catalytic and toxic capabilities that occupies a critical role in pathogenesis of
B. pertussis through its capability to disarm immune cells and manipulate cellular signaling in host
cells [251–253]. Considering the complementary action of PTX and ACT in the pathogenesis of infection,
PTX is crucial for the initial establishment of infection, whereas ACT plays its role during bacterial
persistence in the respiratory tract [254]. In humans, ACT and PTX can cooperatively contribute to
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pathogenesis of B. pertussis infection by establishing the respiratory disease pertussis or whooping
cough [230]. To penetrate the host cell, ACT binds to the target cell membrane by its C-terminal portion
and delivers its catalytic moiety into the cytosol [255]. Nevertheless, the main passage by which
ACT can enter host cells is delivery through outer membrane vesicles [256]. After this membrane
translocation, calmodulin activates the catalytic domain of the toxin and enables it to convert cellular
ATP into cyclic adenosine monophosphate in phagocytic immune cells, such as neutrophils and
macrophages [257–259]. The elevated intracellular cAMP may inhibit phagocytosis [232]. ACT can also
inhibit chemotaxis of macrophages and can induce apoptosis [260–262]. In addition, ACT forms lytic
cation-selective pores in the plasma membrane of target cells, as such, contributing to the perturbation
of ion homeostasis, launching signaling pathways and promoting cell lysis [263]. Pores formed by
ACT are size-tunable and comprise heterogeneous architectures such as lines, arcs, and rings [264].
Depending on the incubation time and toxin concentration, the size of pores evolves differently to
provide a channel for the flux of solutes containing large molecular mass whereas vesicle integrity is
retained [264].
7. Bacillus anthracis
B. anthracis is a Gram-positive/variable encapsulated, rectangular rod-shaped bacterium, capable of
forming endospores, belonging to the genus Bacillus and family Bacillaceae [265]. It is an aerobic or
facultative-anaerobic bacterium that can live everywhere in the environment [266]. By utilizing its
virulence factors, including an anti-phagocytic polyglutamic capsule and the anthrax toxins [267],
B. anthracis infects animals, especially herbivores and humans [266].
Anthrax Toxins
Anthrax toxin is a tripartite AB toxin consisting of three soluble non-toxic proteins released
by B. anthracis [268–270]. These proteins are i) protective antigen (PA) with a molecular weight of
the 83 kDa, ii) the lethal factor (LF), which is a Zn2+-dependent metalloprotease with a molecular
mass of ∼90 kDa and iii) edema factor (EF) which is a Ca2+/calmodulin-dependent adenylate cyclase,
with a molecular mass around 90 kDa [267,271,272]. The PA subunit binds to the extracellular
von Willebrand factor A domain of the cellular Anthrax Toxin Receptor (ATR), a type I membrane
protein [273], while the subunits LF and EF have toxic enzymatic functions [267,271]. Accordingly,
assembly of LF and PA makes Anthrax lethal toxin (LeTx), whereas assembly of EF and PA forms
Anthrax edema toxin (EdTx) [274]. Edema factor (EF) is an adenylate cyclase that increases endothelial
and epithelial monolayer permeability and impairs host defenses through a variety of mechanisms
including inhibition of phagocytosis; lethal factor (LF) is a zinc-dependent protease that cleaves
mitogen-activated protein kinase kinase and causes lysis of macrophages. This helps the bacterium
evade the immune system and to kill the host during a systemic infection.
Inhalation anthrax is the most severe form of anthrax [275], with early symptoms similar to
a cold or the flu, including shortness of breath, mild chest discomfort, and nausea. However,
ultimately potentially lethal severe respiratory failure caused by hemorrhagic mediastinitis and
pulmonary edema can arise [275]. The pathophysiology of inhalational anthrax is determined by the
interaction between two toxins of B. anthracis and a capsule interacting with various cell partners in
host organs [276,277]. This process starts with the inhalation of B. anthracis’ spores [278]. The lungs act
on the one hand as a portal to disseminate spores into the deeper lying organs. On the other hand, the
bacteria or spores have a local impact on pulmonary compartments [278–284]. In both cases, anthrax
toxins play important roles in the establishment of the infection.
Regarding the dissemination through the lungs, so far, three models of inhalational B. anthracis
dissemination have been described. First, spores are transported with an intermediate intracellular step,
such as phagocytosis by AMs, dendritic cells or monocytes and are then transported to the regional
draining lymph nodes [278–280]. Secondly, spores germinate in the lumen of the airways and start
to produce exotoxins and proteases, which cause disruption of the alveolar endothelial-to-epithelial
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barrier and opens up a passage for vegetative bacteria to escape through the disrupted barrier, e.g.,
in lymphatics, injured vessels or vessel walls towards the regional draining lymph nodes [281]. Thirdly,
without affecting the integrity of epithelial cells and through adherence to and internalization by
polarized lung epithelial cells, spores can pass through the cells and exit from the basolateral side
of pneumocytes [283]. In all these three paths, spores or germinated bacteria travel to the local
lymph nodes after crossing the barrier, germinate, replicate, and release toxins, which results in
hemorrhagic mediastinitis [284,285]. Subsequently, bacteria can enter into the bloodstream and
continue proliferating, being systemically disseminated to nearly all organs including lungs [284].
The toxins can locally pervade neighboring cells, such as pulmonary vascular endothelial cells and
thereby cause pulmonary and peripheral edema [285].
Regarding the impact of toxins directly in the lungs, inhaled spores germinate apically at a
mucus-secreting air-liquid interface pulmonary barrier and produce vegetative forms of bacteria with
the ability to produce and release exotoxins as essential factors for the anthrax pathogenesis [286,287].
To review the pathogenicity of anthrax toxins to lungs at the cellular level, it may be more appropriate
to discuss each of the toxins (LeTx and EdTx) separately. Accordingly, it has been shown in a model
of isolated perfused rat lungs that they have different impacts on pulmonary vascular pressures and
permeability [288]. However, in vivo studies revealed that these toxin components may cooperate
synergistically to cause edema formation and cell death. Thus, the concerted action of the two should
not be overlooked in practice [289]. It has been shown in vitro and in vivo that LeTx creates most
characteristics of an anthrax infection including cytokine-independent vascular dysregulation and
collapse, pulmonary vascular constriction, disruption of the rat pulmonary microvascular endothelial
barrier integrity leading to severe blood vessel leakage, pulmonary edema, and disrupted gas exchange
that clinically leads to ALI/ARDS [275,288,290–294].
LeTx can also target alveolar epithelial cells, as they provide the receptor proteins, needed for
the binding of LeTx [295]. LeTx has been shown to provoke actin-rearrangement and to destroy the
formation of desmosomes, which results in the impairment of barrier function and in the reduction
of the epithelial surfactant production [295,296]. LeTx, moreover, inhibited the secretion of KC (the
mouse functional orthologue of human IL-8/CXCL8), IL-6, and MIP-2 [297]. EdTx also indirectly affects
endothelial cells by manipulating the release of inflammatory mediators [298]. It enhances central
actin stress fibers and changes the distribution of VE-cadherin [299]. Noteworthy is that human AMs
are resistant to the immunosuppressive effects of LeTx, which is probably the reason for the lack of
detection of the pathogen in the alveolar surface in animal models as well as in autopsy studies [300].
8. Listeria monocytogenes
L. monocytogenes is a Gram-positive rod-shaped motile intracellular pathogenic bacterium [301].
It is a facultative anaerobic bacterium that is ubiquitously distributed in the environment [302,303].
L. monocytogenes is capable of overpassing four physiological barriers including the intestinal
boundary and blood-brain boundaries, as well as the fetoplacental and alveolar-capillary
barriers [21,304]. L. monocytogenes mainly infects immunocompromised and to a fewer extent also
immunocompetent individuals, including pregnant women, neonates, the elderly, and debilitated
patients, causing gastroenteritis, central nervous infections including meningoencephalitis, cerebritis
or rhombencephalitis, abortion, septicemia and pneumonia [302,304–310]. It should be noted
that pneumonia induction by L. monocytogenes is an event, which predominantly will occur in
immune-compromised individuals.
Listeriolysin O (LLO)
The listerial toxin listeriolysin-O (LLO) is 59 kDa [304] thiol-activated pH-regulated
cholesterol-dependent cytolysin and pore-forming exotoxin [304,311] that can form transmembrane
β-barrel pores with a diameter of up to 35 nm [304,312] in the plasma membrane of host cells [18].
Toxins 2020, 12, 223 14 of 34
Regardless of the destructive nature of membrane perforation, this pore formation provides a passage
for the alteration of ion gradient such as influx of Ca2+ into host cells [16,313,314].
LLO causes a dysfunction in the ENaC channel in airway epithelial cells, especially by targeting
the crucial α subunit [21,315]. ENaC-α is not only crucial for promoting Na+ reabsorption across
Na+-transporting epithelia but also for its role in strengthening capillary barrier function in lung
microvascular endothelial cells [315,316]. Thus, targeting ENaC-α expression impairs structural and
functional properties of ENaC and weakens the capillary barrier function [9,316]. LLO decreases the
expression of ENaC-α at least partially through disabling positive regulators of ENaC including serum
and glucocorticoid-dependent kinase (Sgk-1) and protein kinase B (Akt-1). This in turn decreases
the surface expression and of ENaC- α (as shown in the human bronchiolar epithelial H441 cell
line) and thus the capacity of ENaC to take up Na+ [21]. In addition, the LLO-induced increase
in intracellular Ca2 activates protein kinase C-alpha (PKC-α), which in turn induces capillary leak.
As such, LLO launces at least two different mechanisms that promote pulmonary edema formation:
capillary leak and impaired liquid clearance [21,316–318].
In order to prevent the deleterious actions from LLO on Ca2+ influx, a reaction product of the
phosphatidylcholine-specific phospholipase C (PC-PLC) of L. monocytogenes -phosphocholine (ChoP)-
has the capacity to potently inhibit intra- and extracellular activities of LLO and also of PLY, including
calcium influx, mitochondrial damage, and apoptosis [319].
9. Streptococcus pneumoniae
S. pneumoniae is a slightly pointed coccus or diplococcus and a capsule-forming Gram-positive
pathogenic bacterium. Pneumococci represent the leading cause of bacterial pneumonia and of
community-acquired pneumonia worldwide. Due to its high morbidity and mortality, this disease
represents one of the most important challenges and urgencies in clinical medicine. S. pneumoniae is
also a prominent cause of sepsis, otitis media, and meningitis in adults [320,321]. S. pneumoniae mostly
colonizes in the normal nasopharyngeal flora asymptomatically, but it can cross this niche and migrate
to the brain, the blood, and the lower respiratory tract [23,322,323]. S. pneumoniae can be carried over
from person to person via droplets/aerosols [324]. Among the many colonization and virulence factors
that S. pneumoniae possesses, the pore-forming toxin pneumolysin (PLY) plays a prominent role in the
pathogenesis during lung infection [325].
Pneumolysin (PLY)
PLY is a thiol-activated multifunctional pore-forming exotoxin with a molecular weight of
53 kDa [326,327]. PLY binds free cholesterol and inserts itself into the lipid-rich bilayer of the cell
membrane, where it assembles into a ring containing 30-50 monomers with a diameter of about
35 nm [328,329]. Since these pores are Ca2+ permeable, they promote an increase of intracellular
Ca2+ levels [11,15]. PLY is not actively secreted into the extracellular space [330] but is released as a
result of S. pneumoniae autolysis [9,331] or upon antibiotic treatment [332]. Once released, PLY can
induce profound capillary leak, as such aggravating pulmonary permeability edema associated with
pneumonia [11,322,332], ALI and ARDS [333,334]. PLY can moreover cause acute exacerbation of
idiopathic lung fibrosis (IPF).
In view of its wide range of deleterious activities contributing to ALI, we have summarized PLY’s
actions in the lungs in Figure 1. In the alveolar space, pneumococcal enzyme LytA or autolysin mediate
autolysis of the bacteria thus inducing the release of PLY [321]. In the presence of antibiotics, this release
can lead to high alveolar concentrations of the toxin [331]. When both neutrophils and PLY are present
in the alveolar space, PLY will form pores in the neutrophil membrane, which in turn induces cell death
and/or the release of neutrophil elastase (NE) (Figure 1) [321]. Subsequently, neutrophil elastase will
impair macrophage phagocytic activity and will induce detachment and death of alveolar epithelial
cells and the generation of the neutrophil attractant chemokine IL-8/CXCL8 [321]. In addition to the
above-mentioned impact of PLY on AMs, the toxin can also induce necroptosis in these cells during acute
Toxins 2020, 12, 223 15 of 34
bacterial pneumonia [5]. PLY induces Ca2+-dependent increase of prostaglandin E2 and leukotriene
B4 by both resting and chemoattractant-activated human neutrophils in vitro [335]. In addition,
the pore-forming toxin can increase PAF and thromboxane A2 synthesis by these cells [336]. Apart
from promoting IL-8 generation, PLY also fosters a hepoxilin A3-dependent neutrophil recruitment
across the pulmonary epithelium in a pore-dependent fashion [337].
 
κ
Figure 1. Multiple actions of pneumolysin (PLY) fostering acute lung injury during
S. pneumoniae-induced pneumonia. Autolysis or antibiotics-induced lysis of the pathogen causes
the release of the pore-forming toxin PLY from S. pneumoniae. PLY induces chemokine production in
alveolar epithelial cells, fostering the infiltration of neutrophils and non-resident alveolar macrophages
(AMs) in the alveolar space. PLY induces neutrophil lysis and the release of elastase, which in turn
impairs phagocytosis capacity of AMs. Together these actions will impair immune defense against
S. pneumoniae. PLY furthermore impairs both the alveolar epithelial and capillary barriers through the
disruption of adherens and tight junction proteins and through lytic effects in AT1/2 and microvascular
endothelial cells. Moreover, PLY impairs Na+ uptake in AT1/2 cells, which mediates alveolar fluid
clearance, at least partially through the induction of ENaC dysfunction.
Through its cytotoxic, barrier-disruptive, and complement-activating properties, PLY participates
in the pathogenesis of ALI and promotes bacteremia [332]. PLY’s lytic pores may cause alveolar
hemorrhage and dissemination of alveolar microorganisms into the bloodstream [338–341]. PLY has
also cytotoxic properties, as it can causes caspase 6-dependent apoptosis in lung epithelium and
capillary endothelium [338,339]. Interestingly, different immune cells were shown to exert differential
sensitivity to the pore-forming-induced cytotoxic activities. As such, T cells were shown to be highly
susceptible, whereas alveolar macrophages are more resistant [342]. Plasma membrane damage
caused by cytolysin-induced pore formation can however be repaired through a mechanism involving
Ca2+-activated lipid scramblase TMEM16F, which in turn promotes repair by enhancing membrane
fluidity and the release of extracellular vesicles carrying damaged membranes [343].
PLY-induced damage in lung tissue can be sensed by the NOD-, LRR-, and pyrin domain-containing
protein 3 (NLRP3) inflammasome [344]. However, different pneumococcal serotypes can activate
these innate immune receptors to a different extent and some, such as serotype 1 and 8 isolates
can evade sensing by inflammasomes altogether [344]. NLRP3 protects the alveolar barrier during
pneumococcal PLY-induced ALI by preventing detachment of epithelial cells [345]. PLY activates
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the NLRP3 inflammasome to promote generation of pro-inflammatory cytokines independently of
TLR4 [344,346].
PLY’s role in inflammation is highly complex, since the toxin can induce both pro- and
anti-inflammatory actions. PLY can promote inflammation by means of activating the NF-κB and p38
MAP kinase pathways [11,347,348]. Moreover, in view of its capacity to increase intracellular Ca2+
levels, PLY activates Ca2+-dependent enzymes, including PKC-α [11], which in turn causes inhibitory
phosphorylation of endothelial nitric oxide synthase (eNOS) and barrier dysfunction [321,339,349].
By contrast, PLY binding to the mannose receptor C type 1 (MRC-1) in dendritic cells and AMs was
recently shown to blunt pro-inflammatory cytokine responses and toll-like receptor signaling and to
upregulate the cytokine suppressor SOCS1, as such, facilitating pneumococcal internalization into
non-lysosomal compartments [350]. Increased intracellular Ca2+ provoked by PLY’s pore forming
actions moreover induces pathways targeting mechanisms mediating alveolar liquid clearance. This
predominantly includes vectorial Na+ uptake by the ENaC in AT1/2 cells [9] (Figure 1).
10. Conclusions
Healthy humans are colonized and co-exist with over 100 trillion bacteria as well as significant
numbers of viruses, fungi, and archaea [351]. These microorganisms, thus, outnumber human cells by
about 10–100-fold and constantly interact with the surrounding environment. Microbial infection is
highly relevant to the biological functioning of the respiratory system and, thus, to disease pathogenesis
in the host. The immune system is crucial to protect the lung from infection, as evidenced with, e.g.,
severe neutropenia or acquired immune deficiency syndrome, where pneumonia frequently occurs
and is by far the most frequent infection. Repeated or non-resolving infections may be key events in
pathogenic evolution of chronic pulmonary diseases, such as COPD, CF lung disease, bronchiectasis,
and others. The biological system includes local and systemic inflammation and immune response and
their reparative control mechanisms. During the dynamic interaction with the environment, lungs are
highly influenced by inhalational stressors, such as cigarette smoke, ozone and occupational toxic
agents, as well as by host factors, including the nutrition-, sleep-, and exercise-dependent performance
of our immune defense system. This is further influenced by infectious insults, as documented by
the high susceptibility for severe bacterial pneumonia during the course of influenza virus infection.
Such complications quite frequently lead to respiratory failure or to septic shock. Whereas commensal
organisms may provide the host with a number of benefits (e.g., contributing to metabolism or shaping
immune competence), the vast majority of infections are caused by organisms that are part of the normal
flora (e.g., S. aureus, S. pneumoniae, and P. aeruginosa) [351]. Only relatively few infections are due to
organisms that are strictly pathogens (e.g., Neisseria gonorrhoeae, Treponema pallidum, Mycobacterium
tuberculosis, some non-tuberculous mycobacteria).
In conclusion, bacterial toxins may play a key pathogenic role and are thus of highest relevance in
many instances of infection. The site- and situation-dependent role of bacterial toxins and the adaptive
interplay with the host are crucial factors for the infective potential of the pathogens. Indeed, the role of
bacteria and their toxins seems to be determined by both general and highly specific, time-dependent
local host and environmental factors, as well as by the ecological status of the microbiome [352].
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